Arvinas Inc (ARVN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Arvinas Inc (ARVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11304
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arvinas Inc (Arvinas) is a biopharmaceutical company that develops protein degradation therapeutics. The company develops novel therapeutics for the treatment of pro-inflammatory, cancer, autoimmune and rare diseases. Its proprietary approach is to target disease causing proteins. Arvinas’s protein degradation technology platforms include proteolysis-targeting chimera and hydrophobic tagging which induce the loss of intracellular proteins. The company intends to expand its transformative protein degradation technology and its product candidates into clinical development through collaborations. It also develops degraders for targets in cancer, including androgen receptor, estrogen receptor and BET proteins. Arnivas is headquartered in New Haven, Connecticut, the US.

Arvinas Inc (ARVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arvinas Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Arvinas Raises USD55 Million in Series C Financing 10
Arvinas Raises USD41.6 Million in Series B Venture Financing 12
Arvinas Raises US$18.25 Million In Series A Venture Financing 14
Arvinas Raises USD3.51 Million in Venture Financing 15
Partnerships 16
Arvinas Enters into Co-Development Agreement with Macroceutics 16
Licensing Agreements 17
Pfizer Enters into Licensing Agreement with Arvinas 17
Genentech Expands Licensing Agreement with Arvinas 18
Arvinas Enters into Licensing Agreement with Merck 19
Arvinas Amends Licensing Agreement with Yale University 20
Equity Offering 21
Arvinas Prices IPO of Shares for USD120 Million 21
Arvinas Inc – Key Competitors 23
Arvinas Inc – Key Employees 24
Arvinas Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Corporate Communications 26
Sep 20, 2017: Arvinas Appoints Dr. John Houston as President and Chief Executive Officer 26
Jan 05, 2017: Arvinas Appoints Dr. John Houston as President of Research and Development and Chief Scientific Officer 27
Product News 28
12/20/2017: Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program 28
Clinical Trials 29
Dec 08, 2017: Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium 29
Nov 02, 2017: Arvinas Nominates Oral Clinical Candidate for Androgen Receptor Degrader Program 30
Feb 17, 2017: Arvinas Presents New Preclinical Data on Oral Androgen Receptor PROTAC at ASCO 2017 Genitourinary Cancers Symposium 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Arvinas Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Arvinas Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Arvinas Raises USD55 Million in Series C Financing 10
Arvinas Raises USD41.6 Million in Series B Venture Financing 12
Arvinas Raises US$18.25 Million In Series A Venture Financing 14
Arvinas Raises USD3.51 Million in Venture Financing 15
Arvinas Enters into Co-Development Agreement with Macroceutics 16
Pfizer Enters into Licensing Agreement with Arvinas 17
Genentech Expands Licensing Agreement with Arvinas 18
Arvinas Enters into Licensing Agreement with Merck 19
Arvinas Amends Licensing Agreement with Yale University 20
Arvinas Prices IPO of Shares for USD120 Million 21
Arvinas Inc, Key Competitors 23
Arvinas Inc, Key Employees 24

List of Figures
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Arvinas Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Arvinas Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Arvinas Inc (ARVN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Physio-Control Inc:医療機器:M&Aディール及び事業提携情報
    Summary Physio-Control Inc (Physio-Control), a subsidiary of Stryker Corp, is a manufacturer of emergency medical response products. The company offers lifepak monitor and defibrillator, lifepak CR plus AED, lifepak express AED, lifenet system, data review software, chest true cprcoaching device, lu …
  • Almaty International Airport JSC:企業の戦略・SWOT・財務分析
    Almaty International Airport JSC - Strategy, SWOT and Corporate Finance Report Summary Almaty International Airport JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Meiji Holdings Co, Ltd.
    Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Royal Dutch Shell plc:企業の戦略・SWOT・財務情報
    Royal Dutch Shell plc - Strategy, SWOT and Corporate Finance Report Summary Royal Dutch Shell plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Metabolomic Diagnostics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Metabolomic Diagnostics Ltd (Metabolomic Diagnostics) is an early stage medical diagnostic company that develops technology to provide predictive diagnosis of pre-eclampsia in early pregnancy. The company uses metabolic profiling for investigating the low molecular weight biochemicals existi …
  • Alimentation Couche-Tard Inc. (ATD.B):企業の財務・戦略的SWOT分析
    Alimentation Couche-Tard Inc. (ATD.B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Takashimaya Company, Limited:企業の戦略・SWOT・財務分析
    Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Boardwalk Pipeline Partners LP:企業のM&A・事業提携・投資動向
    Boardwalk Pipeline Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Boardwalk Pipeline Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Nord Gold SE:企業の戦略・SWOT・財務分析
    Nord Gold SE - Strategy, SWOT and Corporate Finance Report Summary Nord Gold SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Nymox Pharmaceutical Corp (NYMX):医療機器:M&Aディール及び事業提携情報
    Summary Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the …
  • Formosa Plastics Corp (1301):企業の財務・戦略的SWOT分析
    Formosa Plastics Corp (1301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Mitsubishi Electric Corporation:企業の戦略・SWOT・財務分析
    Mitsubishi Electric Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Electric Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • JACCS Co., Ltd.:企業の戦略・SWOT・財務情報
    JACCS Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary JACCS Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SNC-Lavalin Group Inc (SNC):電力:M&Aディール及び事業提携情報
    Summary SNC-Lavalin Group Inc. (SNC-Lavalin) is a provider of engineering and construction services. The company offers a range of engineering, procurement, construction, project management services to various industries, which include oil and gas, mining and metallurgy, infrastructure and power. In …
  • Woori Bank:企業の戦略・SWOT・財務情報
    Woori Bank - Strategy, SWOT and Corporate Finance Report Summary Woori Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Balfour Beatty plc:企業の戦略・SWOT・財務分析
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Rothschild Bank AG:企業の戦略・SWOT・財務情報
    Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Genfit SA (GNFT):企業の財務・戦略的SWOT分析
    Summary Genfit SA (Genfit) is a biopharmaceutical company that develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include GFT505, NASH, TGFTX1 and Nitazoxanide (NTZ). Its TGFTX1 is a research p …
  • Patterson-UTI Energy, Inc.:企業の戦略・SWOT・財務情報
    Patterson-UTI Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Patterson-UTI Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Guangzhou Wondfo Biotech Co Ltd (300482):製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Wondfo Biotech Co Ltd (Wondfo) is a biological company that develops, manufactures and supplies rapid diagnostic reagents and related equipment. Its products include rapid quantitative test, immunofluorescent test system, glucose monitoring system, and raw materials. Wondfo also of …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆